Not Yet RecruitingPhase 2ACTRN12605000689673

An initial factorial evaluation of the potential synergy between two novel agents (CB0011 and CB0012) for the treatment of Obstructive Sleep Apnea Syndrome

Sponsor

Cypress Bioscience, Inc

Enrollment

100 participants

Start Date

Sep 3, 2006

Study Type

Interventional

Conditions

Obstructive Sleep Apnea Syndrome

Eligibility

Sex: Both males and femalesMin Age: 21 Yearss

Plain Language Summary

Simplified for easier understanding

This study evaluates whether two experimental drugs (CB0011 and CB0012) work better together than alone for treating obstructive sleep apnea syndrome. Adults aged 21 and older with obstructive sleep apnea may be eligible. Participants would take different combinations of the drugs and have sleep studies to measure changes in breathing during sleep.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A four week 1:1:1:1:1 randomised study in patients with diagnosed Obstructive Sleep Apnea Syndrome. 100 completed patients, 20 to be randomised to CB0012 alone at two different sequential doses, 20 patients to be randomised to 15mg of CB0011 and CB0012 at two different sequential doses, 20 patients to be randomised to 30mg of CB0011 and CB0012 at two different sequential doses, 20 patients to be randomised to CB0011 alone, and 20 patients to be randomised to placebo.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000689673

Related Trials

Functional Magnetic Resonance Imaging in Patients With Obstructive Sleep Apnea Syndrome

NCT051476491 location